a U.S. Army Medical Research Institute of Infectious Diseases , Fort Detrick , MD , USA.
b Nature Technology Corporation , Lincoln , NE , USA.
Hum Vaccin Immunother. 2017 Dec 2;13(12):2837-2848. doi: 10.1080/21645515.2017.1330236. Epub 2017 Jun 12.
A major advantage of DNA vaccination is the ability to induce both humoral and cellular immune responses. DNA vaccines are currently used in veterinary medicine, but have not achieved widespread acceptance for use in humans due to their low immunogenicity in early clinical studies. However, recent clinical data have re-established the value of DNA vaccines, particularly in priming high-level antigen-specific antibody responses. Several approaches have been investigated for improving DNA vaccine efficacy, including advancements in DNA vaccine vector design, the inclusion of genetically engineered cytokine adjuvants, and novel non-mechanical delivery methods. These strategies have shown promise, resulting in augmented adaptive immune responses in not only mice, but also in large animal models. Here, we review advancements in each of these areas that show promise for increasing the immunogenicity of DNA vaccines.
DNA 疫苗的一个主要优势是能够诱导体液和细胞免疫反应。DNA 疫苗目前在兽医领域得到应用，但由于其在早期临床研究中的低免疫原性，尚未在人类中得到广泛认可。然而，最近的临床数据重新确立了 DNA 疫苗的价值，特别是在诱导高水平抗原特异性抗体反应方面。已经研究了几种方法来提高 DNA 疫苗的效力，包括改进 DNA 疫苗载体设计、包含基因工程细胞因子佐剂以及新型非机械传递方法。这些策略显示出了前景，不仅在小鼠中，而且在大型动物模型中，都增强了适应性免疫反应。在这里，我们综述了这些领域的进展，这些进展有望提高 DNA 疫苗的免疫原性。
